Dapsone

Overview

Dapsone is an antimicrobial compound used primarily to treat leprosy and dermatitis herpetiformis. It acts as a bacteriostatic agent by inhibiting bacterial synthesis of dihydrofolic acid.

API suppliers (11)

Suppliers of Dapsone evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• Macleods Pharmaceuticals Ltd.India2 active DMF GMP on record
• ATUL LTDIndia1 active DMF
• Sai Life Sciences LimitedIndia1 active DMF
• NOVITIUM PHARMA LLCUnited States1 active DMF
• Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
• Dipharma Francis SrlItaly1 active DMF GMP on record
• EXTROVIS AGSwitzerland1 active DMF
• COHANCE LIFESCIENCES LTDIndia1 active DMF GMP on record
• MEDILUX LABORATORIES PVT LTDIndia1 active DMF GMP on record
• LUNDBECK PHARMACEUTICALS ITALY SPAItaly1 active DMF GMP on record
• CHONGQING HUAPONT PHARMACEUTICAL CO LTD1 active DMF

EU CEP holders (5)

Companies holding a valid EU Certificate of Suitability (CEP) for Dapsone, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (30 approved US products), the latest listed US patent on Dapsone expires 18 Nov 2033. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

4-(4-aminophenyl)sulfonylaniline

Canonical SMILES

C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N

InChIKey

MQJKPEGWNLWLTK-UHFFFAOYSA-N

Therapeutic areas